Basket | Login | Register

 
 
 
 

Switzerland

Reimbursement of anti-dementia drugs

The availability of medicines in general

The Federal Office for Social Insurance draws up a positive list of pharmaceuticals for which the compulsory health insurance system will pay (the specialty list). Maximum prices are also set for these products. [1]

The availability of Alzheimer treatments

All four anti-dementia drugs are available in Switzerland and are part of the reimbursement system.

Treatment decisions can be made by any doctor whether it is for treatment initiation or treatment continuation. The Swiss system requires the doctor to carry out an MMSE at the time of diagnosis, as well as a first follow up examination after three months which can then be followed by examinations every six months. Treatment with acetylcholinesterase inhibitors should be discontinued if the MMSE score falls below 10 and with memantine for MMSE scores under 3.

There are no restrictions for the reimbursement of people living alone or in nursing homes.

 

Donepezil

Rivastigmine

Galantamine

Memantine

Reimbursement

Yes

Yes

Yes

Yes

Initial treatment decision

No restrictions

No restrictions

No restrictions

No restrictions

Continuing treatment decision

No restrictions

No restrictions

No restrictions

No restrictions

Required examinations

MMSE

MMSE

MMSE

MMSE

MMSE limits

>10

>10

>10

>3

People living alone

No restrictions

No restrictions

No restrictions

No restrictions

People in nursing homes

No restrictions

No restrictions

No restrictions

No restrictions

[1] WHO, Pharmaceuticals in Switzerland, accessed September 2006: Http://www.who.dk/pharmaceuticals/Topics/Overview/20020414_8

 

 
 

Last Updated: mercredi 15 juillet 2009

 

 
 

Options

  • Send this page to a friend